Iida, Shinsuke

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., et al. (2023) · Nature Medicine

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 664

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Usmani, S. Z., Schjesvold, F., Oriol, A., Karlin, L., Cavo, M., Rifkin, R. M., Yimer, H. A., LeBlanc, R., Takezako, N., McCroskey, R. D., et al. (2019) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 251

Rapid Discovery of Highly Potent and Selective Inhibitors of Histone Deacetylase 8 Using Click Chemistry to Generate Candidate Libraries

Suzuki, T., Ota, Y., Ri, M., Bando, M., Gotoh, A., Itoh, Y., Tsumoto, H., Tatum, P. R., Mizukami, T., Nakagawa, H., et al. (2012) · Journal of Medicinal Chemistry

Histone Deacetylase Inhibitors ResearchClick Chemistry and Applications

Cited by 165

Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia

Luo, J.-M., Yoshida, H., Komura, S., Ohishi, N., Pan, L., Shigeno, K., Hanamura, I., Miura, K., Iida, S., Ueda, R., et al. (2003) · Leukemia

Protein Tyrosine PhosphatasesAcute Myeloid Leukemia Research

Cited by 127

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

Harrison, S. J., Minnema, M. C., Lee, H. C., Spencer, A., Kapoor, P., Madduri, D., Larsen, J., Ailawadhi, S., Kaufman, J. L., Raab, M. S., et al. (2020) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 112

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.

Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., et al. (2024) · Blood

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 79

Design, Synthesis, and Biological Activity of NCC149 Derivatives as Histone Deacetylase 8‐Selective Inhibitors

Suzuki, T., Muto, N., Bando, M., Itoh, Y., Masaki, A., Ri, M., Ota, Y., Nakagawa, H., Iida, S., Shirahige, K., et al. (2014) · ChemMedChem

Histone Deacetylase Inhibitors ResearchClick Chemistry and Applications

Cited by 71

Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.

Mateos, M.-V., Nahi, H., Legiec, W., Grosicki, S., Vorobyev, V., Spicka, I., Hungria, V. T., Korenkova, S., Bahlis, N. J., Flogegard, M., et al. (2019) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 25

Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

Hirano, M., Imai, Y., Kaito, Y., Murayama, T., Sato, K., Ishida, T., Yamamoto, J., Ito, T., Futami, M., Ri, M., et al. (2021) · Journal of Experimental & Clinical Cancer Research

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 25